0001790340-26-000057
SEC filingNet loss improved to $13.5M in Q1 2026, driven by lower operating expenses, while cash burn increased to $18.5M as the company prepares for pivotal trials.
Immuneering continues to advance its lead product candidate, atebimetinib, a novel MEK inhibitor. The company expects to initiate the MAPKeeper 301 registrational trial in first-line pancreatic cancer in mid-2026, which will likely drive a meaningful increase in R&D spending. Additionally, updated survival and safety data from an expanded Phase 2a cohort are expected in the second quarter of 2026, and a Phase 1 trial of atebimetinib in combination with Libtayo in non-small cell lung cancer is planned for the second half of 2026. Management expects to continue incurring net losses for the foreseeable future as it invests in clinical development and prepares for potential commercialization.